盐酸缬更昔洛韦片要注意什么事项？

It is an oral anti-cytomegalovirus infection drug developed by Roche of Switzerland and launched in my country in 2006. It is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

What should I pay attention to while using Valganciclovir Hydrochloride Tablets?

1. Acute renal failure: Acute renal failure may occur, ensure adequate hydration, and use with caution in patients receiving concomitant nephrotoxic drugs.

2. Hematological diseases: severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia and bone marrow failure, including aplastic anemia. May occur at any time during treatment and worsen with continued use; cell counts usually begin to recover within 3-7 days of stopping treatment.

Do not use if the absolute neutrophil count is <500 cells/MM3, platelet count <25,000/m3, or hemoglobin <8 g/dl; use with caution in patients with myelosuppression, cytopenia, or patients receiving myelosuppressive drugs/radiation. Monitor CBC and platelet counts at baseline and frequently during treatment, especially in infants and patients with renal impairment, patients with prior drug-induced leukopenia, and patients with neutrophil counts <1000 cells/mm3 at the start of treatment.

3. Carcinogenicity/teratogenicity: It may temporarily or permanently inhibit sperm production and fertility; it may cause birth defects and cancer in humans. Due to its teratogenicity, women should take a pregnancy test before initiating pregnancy and use effective contraception during treatment and for 30 days after treatment; men should use barrier contraception during treatment and for 90 days after treatment.

4. Renal impairment: Use with caution in patients with impaired renal function; dose adjustment is required.

5. Elderly: Acute renal failure may occur in elderly patients with or without renal damage. Use with caution and adjust dosage according to renal function.

6. Liver transplant recipients: Not suitable for liver transplant patients (a higher incidence of tissue-infiltrating cytomegalovirus (CMV) was observed in the trial compared with oral ganciclovir).